Biomea Fusion’s (BMEA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research report report published on Monday morning,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright also issued estimates for Biomea Fusion’s Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.03) EPS and Q4 2025 earnings at ($1.11) EPS.

BMEA has been the topic of several other reports. Oppenheimer set a $10.00 price objective on Biomea Fusion in a research report on Monday, March 24th. D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price target on shares of Biomea Fusion in a report on Wednesday, March 19th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.91.

Biomea Fusion Price Performance

Shares of NASDAQ:BMEA opened at $2.16 on Monday. The company has a market capitalization of $78.28 million, a PE ratio of -0.54 and a beta of -0.26. The business has a fifty day moving average price of $3.19 and a 200-day moving average price of $5.89. Biomea Fusion has a 1-year low of $1.87 and a 1-year high of $14.43.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.19. On average, sell-side analysts anticipate that Biomea Fusion will post -3.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BMEA. Wellington Management Group LLP bought a new stake in shares of Biomea Fusion during the 4th quarter valued at about $317,000. Wexford Capital LP boosted its holdings in shares of Biomea Fusion by 2.3% in the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company’s stock worth $517,000 after buying an additional 3,007 shares during the last quarter. Two Sigma Advisers LP grew its position in Biomea Fusion by 290.7% during the fourth quarter. Two Sigma Advisers LP now owns 459,500 shares of the company’s stock valued at $1,783,000 after buying an additional 341,900 shares during the period. Two Sigma Investments LP increased its holdings in Biomea Fusion by 104.4% during the fourth quarter. Two Sigma Investments LP now owns 559,930 shares of the company’s stock valued at $2,173,000 after buying an additional 286,049 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Biomea Fusion in the fourth quarter worth approximately $766,000. Institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.